Tumor tissue will undergo testing for changes in more than 160 genes. If a patient's tumor has a genetic change that matches one targeted by a drug used in the trial, the patient may be eligible to join the treatment arm targeting that genetic change.

FREDERICK, Md. -- The National Cancer Institute–Children’s Oncology Group trial known as Pediatric MATCH (Molecular Analysis for Therapy Choice) trial launched in 2017, with significant operations and technical support from the Frederick National Laboratory for Cancer Research. Focusing on patients aged 1–21, Pediatric MATCH seeks to determine whether precision medicines that are designed to treat specific cancers with certain mutations can also treat other cancers with the same mutations.